Suppr超能文献

体外比较杀微生物剂预防上皮内阴道细胞中 HIV-1 基因组整合的功效。

Ex vivo comparison of microbicide efficacies for preventing HIV-1 genomic integration in intraepithelial vaginal cells.

机构信息

Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.

出版信息

Antimicrob Agents Chemother. 2010 Feb;54(2):763-72. doi: 10.1128/AAC.00891-09. Epub 2009 Nov 30.

Abstract

Vaginally applied microbicides hold promise as a strategy to prevent sexual HIV transmission. Several nonspecific microbicides, including the polyanion cellulose sulfate, have been evaluated in large-scale clinical trials but have failed to show significant efficacy. These findings have prompted a renewed search for preclinical testing systems that can predict negative outcomes of microbicide trials. Moreover, the pipeline of potential topical microbicides has been expanded to include antiretroviral agents, such as reverse transcriptase, fusion, and integrase inhibitors. Using a novel ex vivo model of vaginal HIV-1 infection, we compared the prophylactic potentials of two forms of the fusion inhibitor T-20, the CCR5 antagonist TAK-778, the integrase inhibitor 118-D-24, and cellulose sulfate (Ushercell). The T-20 peptide with free N- and C-terminal amino acids was the most efficacious compound, causing significantly greater inhibition of viral genomic integration in intraepithelial vaginal leukocytes, measured by an optimized real-time PCR assay, than the more water-soluble N-acetylated T-20 peptide (Fuzeon) (50% inhibitory concentration [IC50], 0.153 microM versus 51.2 microM [0.687 ng/ml versus 230 ng/ml]; P<0.0001). In contrast, no significant difference in IC50s was noted in peripheral blood cells (IC50, 13.58 microM versus 7.57 microM [61 ng/ml versus 34 ng/ml]; P=0.0614). Cellulose sulfate was the least effective of all the compounds tested (IC50, 1.8 microg/ml). These results highlight the merit of our model for screening the mucosal efficacies of novel microbicides and their formulations and potentially rank ordering candidates for clinical evaluation.

摘要

阴道应用杀微生物剂作为预防性传播 HIV 的策略具有一定的前景。几种非特异性杀微生物剂,包括多阴离子硫酸纤维素,已经在大规模临床试验中进行了评估,但未能显示出显著的疗效。这些发现促使人们重新寻找可预测杀微生物剂试验阴性结果的临床前检测系统。此外,潜在的局部杀微生物剂管道已扩展到包括抗逆转录病毒药物,如逆转录酶、融合和整合酶抑制剂。我们使用阴道 HIV-1 感染的新型离体模型,比较了两种融合抑制剂 T-20 形式、CCR5 拮抗剂 TAK-778、整合酶抑制剂 118-D-24 和硫酸纤维素(Ushercell)的预防潜力。带有游离 N-和 C-末端氨基酸的 T-20 肽是最有效的化合物,与更水溶性的 N-乙酰化 T-20 肽(Fuzeon)相比,导致上皮内阴道白细胞中病毒基因组整合的抑制作用显著增强,通过优化实时 PCR 测定法测量,其 50%抑制浓度(IC50)为 0.153 microM,而后者为 51.2 microM(0.687 ng/ml 对 230 ng/ml;P<0.0001)。相比之下,在外周血细胞中未观察到 IC50 显著差异(IC50,13.58 microM 对 7.57 microM [61 ng/ml 对 34 ng/ml];P=0.0614)。所有测试化合物中,硫酸纤维素的效果最差(IC50,1.8 microg/ml)。这些结果突出了我们的模型在筛选新型杀微生物剂及其制剂的粘膜功效方面的优势,并可能对候选药物进行临床评估的排序。

相似文献

7
The potential for HIV fusion inhibition.HIV融合抑制的潜力。
Curr Opin Infect Dis. 2001 Feb;14(1):13-6. doi: 10.1097/00001432-200102000-00003.
9
Will integrase inhibitors be used as microbicides?整合酶抑制剂会被用作杀微生物剂吗?
Curr HIV Res. 2012 Jan 1;10(1):36-41. doi: 10.2174/157016212799304706.
10
HIV entry and fusion inhibitors.HIV进入和融合抑制剂。
Expert Opin Emerg Drugs. 2004 May;9(1):1-7. doi: 10.1517/eoed.9.1.1.32950.

引用本文的文献

9
Rectal microbicide development.直肠用杀微生物剂的研发
Curr Top Microbiol Immunol. 2014;383:117-36. doi: 10.1007/82_2013_325.

本文引用的文献

3
Vaginal microbicides and the prevention of HIV transmission.阴道杀菌剂与HIV传播的预防
Lancet Infect Dis. 2008 Nov;8(11):685-97. doi: 10.1016/S1473-3099(08)70254-8.
6
Whither or wither microbicides?杀菌剂何去何从?
Science. 2008 Jul 25;321(5888):532-4. doi: 10.1126/science.1160355.
8
Enhancement of HIV infection by cellulose sulfate.硫酸纤维素增强HIV感染
AIDS Res Hum Retroviruses. 2008 Jul;24(7):925-9. doi: 10.1089/aid.2008.0043.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验